Researchers and people who work in the pharmaceutical industry can make better treatment plans by understanding how antiviral drugs work at the molecular level. GS-441524 powder is a great nucleoside analogue that targets viral RNA-dependent RNA polymerase. This makes it a useful chemical in the fight against different RNA virus illnesses. This way of fighting viruses works by messing up the basic processes that viruses use to copy themselves inside human cells.
The chemical works by using a complex molecular method to look like natural nucleotides while stopping the replication of viruses at the same time. By adding itself to the growing RNA chain while the virus is replicating, this nucleoside equivalent blocks further production at the molecular level. This process works especially well against the feline infectious peritonitis virus, and it has caught the attention of research groups that are looking into similar RNA viruses.
Figuring out the exact way that GS-441524 powder stops RNA polymerase is very important for understanding how it can be used in medicine. The compound is a good option for developing an antiviral medicine because it can carefully target viral enzymes while causing minimal damage to host cell processes. This piece goes into great depth about the chemical interactions that happen when this nucleoside analogue meets viral RNA polymerase.
GS 441524 Powder CAS 1191237-69-0
1.General Specification(in stock)
(1)Injection
20mg, 6ml; 30mg,8ml; 40mg,10ml
(2)Tablet
25/45/60/70mg
(3)API(Pure powder)
(4)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-1-049
GS-441524 CAS 1191237-69-0
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GS 441524 Powder, please refer to the following website for detailed specifications and product information.
How Does GS-441524 Powder Block RNA-Dependent RNA Polymerase Function?
When GS-441524 powder gets into affected cells and goes through cytoplasmic phosphorylation, it starts to stop the infection. This metabolic change turns the molecule into its active triphosphate form, which is very similar to the adenosine triphosphate that virus polymerases usually use. Because the structures are so identical, the changed nucleotide can trick the viral enzyme into adding it to the RNA that is being made.
RNA-dependent RNA polymerase is the main part of an RNA virus that copies itself. This enzyme reads the virus genome code and builds new RNA strands by adding nucleotides one at a time. The polymerase can recognise certain chemical parts on nucleotides that come in, such as the sugar molecule, phosphate groups, and nitrogenous bases. The triphosphate form of this antiviral molecule has the right structure to meet the recognition needs of the enzyme, so it can compete with natural substrates for inclusion.
A very important part of the process is the competitive blocking part. The polymerase binding site turns into a battlefield during active viral replication, where natural nucleotides and the changed copy fight for inclusion. The amount of GS-441524 powder compared to the nucleotide pools in cells directly affects how often analogues are incorporated. The polymerase is more likely to choose the modified nucleotide over its normal version when the concentration is higher.
During the first selection step, research has shown that the enzyme can't tell the difference between the modified nucleotide and normal adenosine triphosphate. The substance can get around the polymerase's quality control systems because it looks like a different molecule. The enzyme then speeds up the formation of the phosphodiester bond that connects the changed nucleotide to the growing RNA chain. This sets the stage for replication failure without being aware of it.
The molecular changes in this nucleoside counterpart, especially the replacement of the 1'-cyano group on the ribose sugar, cause small changes in the shape that become important only after they are added. These changes don't stop bond formation right away; instead, they cause structural limits that show up in later rounds of elongation. Nucleoside analogues are different from other types of antiviral substances that stop enzymes from working by directly occupying their active site. They do this through a delayed disruption process.
GS-441524 Powder and Termination of Viral RNA Chain Elongation Process
Combining GS-441524 powder with new virus RNA strands leads to chain termination, which is the end result. The polymerase tries to keep extension going by adding the next nucleotide after the changed nucleotide joins the growing chain. The copy changes the structure in a way that limits the geometry of the enzyme's active site, making it impossible for the next nucleotide to enter properly.
During the making of RNA, the 3'-hydroxyl group on natural ribose sugars acts as a link for the next nucleotide. For each elongation cycle, a new phosphodiester link is made between this 3'-hydroxyl group and the triphosphate of the next nucleotide. Because this antiviral compound's structure has been changed, the functional groups are no longer arranged in the same way. This makes it physically impossible for the polymerase to speed up the next bond formation process.
Biochemical tests have shown that chain termination doesn't always happen right away after analogue insertion. Some polymerases can add one or two more nucleotides past the inclusion spot before they stop working completely. This delayed termination pattern happens because the enzyme is structurally flexible and can handle small changes in the RNA-enzyme complex. It depends on the viral polymerase and the sequence environment around the incorporation site to know exactly where the process ends.
The RNA chains that have been cut off stay connected to the polymerase enzyme for a while before breaking apart. The incomplete RNA product and the polymerase enzyme are essentially taken away by this long-lasting association, removing them from the pool of working replication machinery.The virus's ability to make new genetic copies slowly decreases as stopped complexes build up, resulting in a huge drop in the production of viral particles.
Measurements of RNA synthesis in the presence of GS-441524 powder show that the average length of newly synthesised viral RNA strands gets shorter as the concentration goes up. Some full-length transcripts still form in smaller amounts, but a lot of them are cut off too soon.
As concentrations rise, the chance of analogue inclusion during any given elongation cycle also rises. This makes average transcript lengths lower and stops virus replication more completely.
The fact that the chain ending can't be undone makes this technique very useful. The covalent inclusion of the modified nucleotide makes a lasting block, unlike reversible enzyme inhibitors that can break apart and let the enzyme start working again. The sick cell can't easily fix or get rid of the equivalent from chains that have ended. This keeps the antiviral activity going for the whole half-life of the compound inside the cell.
What Happens During Polymerase Binding Inhibition by GS-441524 Powder?
The first contact between the virus RNA polymerase and the triphosphate form of this nucleoside analogue takes place in the nucleotide-binding pocket of the enzyme. This unique space inside the polymerase active site has evolved to recognise and link natural nucleoside triphosphates very specifically. Many amino acid residues are in the pocket. They interact with the ribose sugar, form hydrogen bonds with the base, and make electrostatic contacts with the negatively charged triphosphate groups.
When the changed nucleotide gets into this binding pocket, the polymerase's recognition residues interact with the molecular features of the copy. In the same way that natural adenosine triphosphate does, the adenine base part makes hydrogen bonds with amino acids that are complementary. The triphosphate part reacts with positively charged residues, usually magnesium ions arranged by aspartate residues, which makes the reaction easier. These common interactions help explain why the enzyme can't tell the difference between the mimic and natural substrates when it first binds them.
The important molecular difference caused by the 1'-cyano change doesn't have a big effect on the initial binding affinity. Crystallographic studies of similar nucleoside analogues bound to viral polymerases show that the active site of the enzyme can fit the changed sugar structure without major changes in shape during the binding phase. This is the reason why GS-441524 powder can compete with natural nucleotides even though its structure has changed.
After attaching, the polymerase changes shape to put the attached nucleotide in the right place for activation. When the enzyme closes around the substrate, it lines up the active residues perfectly so that a phosphodiester bond can form. The changed parts of GS-441524 powder don't stop the necessary structural shifts during this change, so the catalytic cycle can continue. The enzyme successfully speeds up the nucleotidyl transfer process, which adds the copy to the RNA chain.
The problems start to show up in the next binding cycle. Once a nucleotide is added, the polymerase has to move along the template, removing it from the active site and placing it in a place where the next nucleotide can join. The copy changes the structure in a way that causes steric clashes or bad interactions during the translocation step or when trying to join the next nucleotide, which stops the elongation process in its tracks.
GS-441524 Powder Role in Halting Viral Genome Replication at the Enzymatic Level
The replication of viral genomes depends on RNA-dependent RNA polymerase molecules working together along template strands in an organised way. To make viral parts that work, each processor has to finish making full-length genomic or antigenomic RNA. The GS-441524 powder gets in the way of this important process and makes incomplete RNA products that can't do their biological jobs.
The effects on enzymes go beyond just breaking the chain. When polymerase groups get stuck, they can block access to the template, which stops other polymerase molecules from starting synthesis on the same template area. This blocking effect makes each integration event stronger because a single complex that has been broken down can stop multiple possible transcription start events. The combined effect slows down the production of virus RNA by a huge amount.
Cell quality control systems can spot RNA-protein complexes that aren't working right, which are made by polymerases that have stopped working. These monitoring systems can target the incomplete RNA products for degradation, which further reduces the number of virus RNA molecules that might work. The mix of less synthesis and more degradation has a strong stopping effect on the growth of virus genomes.
Based on how their polymerase works, different RNA viruses react differently to this nucleoside variant. The copy may be added less often by enzymes with higher fidelity and stricter substrate selection, while polymerases with lower fidelity can easily accept the changed nucleotide. The range of antiviral activity seen in different virus species is due in part to these changes in enzyme selectivity.
The way that polymerase blockage changes over time affects how well a patient does.
Rapid integration and termination cause viral RNA levels to drop quickly, which could stop productive cases from starting if treatment starts early. Delayed treatment lets viral populations grow before prevention takes effect, so the chemical has to be exposed for a long time to lower viral loads to levels where the immune system can get rid of them.
It is possible for GS-441524 powder to work better with other antiviral processes when used together. Compounds that target different steps of the virus life cycle work with the polymerase inhibition mechanism to stop adaptive reactions and make it less likely that resistance will develop. These kinds of mix techniques look like good ways to make therapies work better.
Step-by-Step Molecular Disruption of RNA Polymerase Caused by GS-441524 Powder
The chemical breakdown process starts with this nucleoside analogue being taken up by cells. Transport proteins make it easier for the chemical to get through the cell walls and into the cytoplasm, which is where viruses replicate. Intracellular kinases find the molecule and start the phosphorylation process that changes it into the active triphosphate form. Before getting to the triphosphate state, this chemical action process usually goes through monophosphate and diphosphate stages.
When GS-441524 powder is changed into its triphosphate form, it mixes with natural nucleoside triphosphates in the nucleotide pool of cells. The concentration reached is based on the amount given, how well cells take it in, and how fast phosphorylation and dephosphorylation happen. Maintaining the right amount of intracellular triphosphate throughout the dosing period keeps the antiviral pressure on viruses that are copying itself steady.
The most important choice point is the polymerase selection event. Both natural ATP and the tweaked counterpart can be used as substrates when the viral polymerase active site is empty and ready to take the next nucleotide. Through short-lived binding interactions, the polymerase's binding pocket checks for available nucleotides. The changed nucleotide meets the enzyme's selection criteria because its structure is similar to that of normal ATP.
Once the polymerase decides to add the chosen nucleotide, the catalytic process starts. The enzyme places catalytic residues and metal cofactors in a way that makes it easier for the 3'-hydroxyl group of the growing chain to attack the α-phosphate of the nucleoside triphosphate that is coming in. The phosphodiester link is made during this process, which also releases pyrophosphate. Even though the structure changes, the chemical change goes through properly, attaching the copy covalently to the new RNA strand.
Translocation comes after inclusion because the polymerase needs to move along the template by one nucleotide to keep growth going. Coordinated structural changes within the enzyme cause this mechanical movement. These changes move the newly added nucleotide from the incorporation site to the upstream spot. The changed structure of the added copy causes small changes in the shape of the RNA backbone that add up to stress during the transfer attempt.
When the polymerase tries to join the next nucleotide that comes in, the end phase shows up. The added GS-441524 powder changes the shape of the particles, which stops the substrate binding spot from properly aligning with the nucleotides that are coming in. Because of the way the structure is set up, the enzyme may try over and over again but fail to connect and absorb the next nucleotide. The complex eventually stops moving and stops making RNA, which is the end of that RNA synthesis event.
Conclusion
The way that GS-441524 powder stops viral RNA polymerase working is a beautiful example of structure-based antiviral design. This nucleoside analogue stops the replication of viral genomes at many levels, including through molecular imitation, competitive inclusion, and delayed chain termination. Nucleoside analogues have been proven to be effective antiviral drugs because they can selectively target viral polymerases while still being safe.
By understanding these molecular features, we can make treatment plans more effective and create next-generation analogues with better qualities. The effects that rely on focus, the setting of the order, and the way time flows all present chances to improve therapy. More study into how polymerase and inhibitors work together should lead to better chemicals that are more effective against a wider range of viruses and are less likely to be resistant.
This method works well against RNA viruses, which shows how important it is to target key viral enzymes. As new viruses come out, the rules that have been set by studying substances like GS-441524 powder will help people act quickly. The best modern antiviral drug research comes from combining a deep knowledge of how things work with real-world clinical use.
FAQ
1. What makes GS-441524 powder effective against RNA viruses?
+
-
Because the compound's structure is similar to natural adenosine, it can be added to virus RNA chains while they are copying themselves. Once added, the changed structure stops the chain from getting longer, which stops the viral genome from being made. This method targets the virus RNA-dependent RNA polymerase enzyme and doesn't have much of an effect on the host cell polymerase enzymes. This makes the antiviral action selective.
2. How long does it take for GS-441524 powder to inhibit viral replication?
+
-
Once the molecule hits the right level inside cells and is phosphorylated to its active triphosphate form, it starts to block the signal. This biochemical stimulation usually happens a few hours after the drug is given. After being added to new viral RNA chains, the chain termination process slows down viral RNA production over the next few hours to days, based on the starting viral load and treatment dose.
3. Can viral polymerases develop resistance to GS-441524 powder?
+
-
It is still possible to build resistance by changing parts of the viral RNA polymerase in ways that make it harder for analogues to be incorporated or make it easier to tell the difference between normal nucleotides and the changed analogue. Because the compound and natural substrates are very close structurally, these resistance changes don't happen very often. They also make it harder for the enzyme to incorporate natural nucleotides successfully. Combination treatments and the right way to dose drugs can help keep resistance from developing.
Partner with BLOOM TECH: Your Trusted GS-441524 Powder Supplier
BLOOM TECH is a dependable company that can provide you with GS-441524 powder. They have more than 12 years of experience in chemical chemistry and pharmaceutical intermediates. Our 100,000-square-meter GMP-certified production facilities, which are cleared by the US-FDA, EU-GMP, and CFDA, make sure that every batch meets the highest quality standards. Our dedication to excellence is shown by the fact that we work with 24 big foreign pharmaceutical companies and R&D agencies. Our three-layer quality control method makes sure that every shipment meets strict requirements, and we'll give you a full refund for any goods that don't. We have clear prices with set profit margins, accurate lead times that can be watched through our ERP platform, and all the paperwork you need to clear customs easily. Whether you need small amounts for study or a lot of them for production, our expert team can help you find a solution that fits your needs. Get in touch with our knowledgeable sales team at Sales@bloomtechz.com to talk about your GS-441524 powder needs and find out how our focus on quality and low prices can help you reach your antiviral research and development goals.
References
1. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-441524 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-385.
2. Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis virus in tissue culture and experimental cat infection studies. Veterinary Microbiology. 2018;219:226-233.
3. Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-441524) for the treatment of Ebola and emerging viruses. Journal of Medicinal Chemistry. 2017;60(5):1648-1661.
4. Yan VC, Muller FL. Advantages of the parent nucleoside GS-441524 over remdesivir for COVID-19 treatment. ACS Medicinal Chemistry Letters. 2020;11(7):1361-1366.
5. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Journal of Biological Chemistry. 2020;295(20):6785-6797.
6. Pedersen NC, Perron M, Bannasch M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2019;21(4):271-281.